This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
Low-dose luteinizing hormone—releasing hormone (LHRH) therapy originated at the University of Michigan Medical School, Ann Arbor, where investigators have given the peptide to diverse subjects including hypogonadal men and anorectic girls.
Previously, says John C. Marshall, MD, professor of internal medicine at the university, European investigators had been giving whopping doses of LHRH (20 to 50 times the doses given to prepubertal men) to hypogonadotropic patients. Although these were administered in pulsatile fashion, they came close to effecting continuous circulation of LHRH, which inhibits rather than stimulates gonadotropin release. Such inhibition is the basis for investigations of LHRH as a contraceptive but is obviously antitherapeutic for gonadotropin deficiency (see accompanying story).
After estimating the portal plasma concentration of endogenous LHRH in normal men, Marshall— along with Robert P. Kelch, MD, professor and chairman of the Department of Pediatrics, and co-workers—gave small doses (0.0125 to 0.05 μg/kg of LHRH to various
Seeking the source of sexual maturation. JAMA. 1982;248(10):1157–1158. doi:10.1001/jama.1982.03330100009003
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: